Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AB126
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aruna Receives FDA IND Clearance for AB126, First Exosome in Trials
Details : AB126 is an unmodified neural-derived exosome that can traverse the blood-brain barrier, showing anti-inflammatory and neuroprotective properties for acute ischemic stroke treatment.
Product Name : AB126
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : AB126
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB126
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB126, an unmodified exosome derived from neural stem cells, has broad therapeutic, which is investigated in superoxide dismutase 1 amyotrophic lateral sclerosis (ALS) mouse model.
Product Name : AB126
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 09, 2023
Lead Product(s) : AB126
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB126
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : University of Georgia Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Aruna Bio Announces Issuance Of A New Composition Of Matter Patent Covering Neural Exosomes In Japan
Details : AB126 are allogenic neural exosomes derived from neural stem cells, is highly effective at crossing the blood/brain barrier – so it can carry other molecules across.
Product Name : AB126
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 13, 2022
Lead Product(s) : AB126
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : University of Georgia Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB126
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB126 is an unmodified neural-derived exosome with the innate ability to cross the blood-brain barrier. AB126 is designed to provide potential therapeutic benefit in its native form for multiple different neurological indications.
Product Name : AB126
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : AB126
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB126
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : National Institute of Neurological Disorders and Stroke
Deal Size : Undisclosed
Deal Type : Funding
Aruna Bio Advances Therapeutic Development for Traumatic Brain Injury
Details : The award will support advancement of AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI).
Product Name : AB126
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 31, 2022
Lead Product(s) : AB126
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : National Institute of Neurological Disorders and Stroke
Deal Size : Undisclosed
Deal Type : Funding